Search

...Xgeva (denosumab) is a human monoclonal antibody that is a RANK (receptor activator of nuclear factor kappa-B) ligand inhibitor. Xgeva is indicated for certain individuals with bone metastases from solid...

...Cryotherapy, also called cryosurgery or cryoablation, is a non-surgical treatment option that uses freezing cold temperatures to kill cancer cells. Cryotherapy is less invasive than surgery and typically has a...

...Chemotherapy is a systemic (meaning whole body) treatment option indicated for many different types of cancer and other conditions. Chemotherapies indicated for cancer treatment are drugs that have antineoplastic properties...

...Perhaps one of the more troubling characteristics of prostate cancer is that common signs and symptoms of the condition typically do not appear until the cancer has grown substantially, or...

...Unfortunately, successfully battling cancer does not ensure that you will never have cancer again in your lifetime. Regardless of what kind of cancer you have, how advanced the cancer was...

... ...

...Whether you’ve just been diagnosed with prostate cancer, are currently undergoing treatment, or have successfully completed treatment, there is always a chance that your prostate cancer can spread, or metastasize...

...There are a variety of different screening options, diagnostic tests, imaging techniques and procedures that can be used to determine if an individual has prostate cancer and how far their...

...If you or your doctor suspect that you may have prostate cancer, or think you should be screened for prostate cancer, the first step in the diagnostic process is investigating...

...Although PSA (prostate-specific antigen) tests, digital rectal exams (DRE’s), and core needle biopsies are tools used to obtain a prostate cancer diagnosis, there are still several conditions that can be...

...The median age of prostate cancer diagnosis is 66 years old, with the highest proportion of those diagnosed between 65 and 74 years old, followed closely by those between 55...

...When prostate cancer is diagnosed in people younger than age 55, it is called early-onset prostate cancer. Younger people with prostate cancer tend to have worse health outcomes. In fact...

...Although the median age of prostate cancer diagnosis is 66 years old, and the highest proportion of individuals are diagnosed between 65 and 74 years old, the condition can develop...

...Zoladex (goserelin) is a Gonadotropin Releasing Hormone (GnRH) agonist (also called LHRH agonists). It is indicated for use as a palliative treatment option for individuals with advanced carcinoma of the...

...Trelstar (triptorelin) is a Gonadotropin Releasing Hormone (GnRH) agonist (or LHRH agonist). It is indicated for use as a palliative treatment option for individuals with advanced prostate cancer. Triptorelin is...

...Vantas (histrelin) is a Gonadotropin Releasing Hormone (GnRH) agonist (or LHRH agonist). It is indicated for use as a palliative treatment option for individuals with advanced prostate cancer. Vantas is...

...Flutamide (Eulexin®) is a drug used to treat prostate cancer. It can be used for prostate cancer that is locally confined or prostate cancer that has spread to other areas...